Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers
1 other identifier
observational
500
1 country
1
Brief Summary
The purpose of the study is to collect different samples for molecular characterization of inflammatory skin diseases.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2023
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 9, 2023
CompletedFirst Posted
Study publicly available on registry
August 16, 2023
CompletedStudy Start
First participant enrolled
October 17, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
August 1, 2028
March 30, 2026
March 1, 2026
4.8 years
August 9, 2023
March 25, 2026
Conditions
Outcome Measures
Primary Outcomes (2)
Untargeted biomarker approach with gene expression profile of skin samples
Day 1
Exploratory biomarker and gene expression analyses.
Day 1
Study Arms (7)
Healthy volunteers
Healthy adults
Acne
Adult subjects aged 18 to 45 years old with acne
AD
Adult subjects with Atopic Dermatitis (AD)
CHE
Adult subjects with Chronic Hand Eczema (CHE)
HS
Adult subjects with Hidradenitis suppurativa (HS)
PPP
Adult subjects with Palmoplantar pustulosis (PPP)
Psoriasis
Adult subjects with Psoriasis
Interventions
biomarkers and optional genetic analysis
biomarkers analysis
biomarkers analysis
Eligibility Criteria
Approximately 200 healthy volunteers and approximately 300 subjects with acne, atopic dermatitis (AD), chronic hand eczema (CHE), hidradenitis suppurativa (HS), palmoplantar pustulosis (PPP), and/or psoriasis will be included in this study.
You may qualify if:
- All subjects:
- Subject is willing to participate and is capable of giving informed consent. Note: Consent must be obtained prior to any study-related procedures.
- Subject must be willing to comply with all study procedures and must be available for the duration of the study.
- Healthy volunteers:
- Male or female subject aged 18 years or older, at the time of consent.
- Subject is in good general health, according to the investigator's judgment.
- Subjects with Acne:
- Male or female subject aged 18 to 45 years old, inclusive, at the time of consent.
- Subjects with AD:
- Male or female subject aged 18 years or older, at the time of consent.
- Subject has clinically confirmed diagnosis of active AD, according to Hanifin and Rajka criteria.
- Subjects with CHE:
- Male or female subject aged 18 years or older, at the time of consent.
- Subject has at least a 6-month history of CHE before Screening (information obtained from medical chart or subject's physician, or directly from the subject).
- Subjects with HS:
- +7 more criteria
You may not qualify if:
- All subjects:
- Subject is a female who is pregnant or who is planning to become pregnant during the study.
- Subject has a history of skin disease or presence of skin condition that, in the opinion of the investigator, would interfere with the study assessments.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Innovaderm Research Inc.
Montreal, Quebec, H2X 2V1, Canada
Biospecimen
Blood, stool, saliva, skin sample, lipid, sebum, microbiome, microorganism, hair, draining fluid
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Robert Bissonnette, MD
Innovaderm Research Inc.
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 9, 2023
First Posted
August 16, 2023
Study Start
October 17, 2023
Primary Completion (Estimated)
August 1, 2028
Study Completion (Estimated)
August 1, 2028
Last Updated
March 30, 2026
Record last verified: 2026-03
Data Sharing
- IPD Sharing
- Will not share